



**DR MICHAEL ELLIS BM MA  
MSC FRCP FACP FIDSA  
MEWI Assoc FFLM(DLM)**

Full Curriculum Vitae





## INDEX

Page	Contents
2-3	Index
4	General and personal details
5-7	Education and Training <ul style="list-style-type: none"> <li>• Schools and University</li> <li>• Honours and awards</li> <li>• Academic examinations pre-university</li> <li>• Professional examinations, degrees and certificates</li> <li>• Postgraduate education and positions held</li> </ul>
8-9	Professional Senior Appointments
10	Medico-legal activities
11	Sample medicolegal cases
12	General Medical Council Revalidation Activities
13-16	Achievements <ul style="list-style-type: none"> <li>• Accomplishments in the Middle East             <ul style="list-style-type: none"> <li>◦ King Faisal Specialist Hospital and Research Centre</li> <li>◦ HCI International Medical Centre, Glasgow</li> <li>◦ Tawam Hospital, UAE</li> <li>◦ Faculty of Medicine and Health Sciences, UAE</li> </ul> </li> <li>• Membership of Learned Societies</li> <li>• Special Clinical Experience</li> </ul>
17-18	Clinical and Research Activities <ul style="list-style-type: none"> <li>• Clinical</li> <li>• Research Interests</li> <li>• Selected Research activities and projects</li> <li>• Other current Research topics</li> <li>• Awards and Grants</li> </ul>
19-20	Teaching Activities <ul style="list-style-type: none"> <li>• Previous teaching activities</li> <li>• Undergraduate teaching at FMHS</li> <li>• Postgraduate teaching at FMHS</li> </ul>

21-25

**Administrative/Committees**

- UK
- Saudi Arabia
- UAE Tawam Hospital
- UAE FMHS

26

**International Activities**

- International Medical Journal Reviewer
- International Groups

27-50

**Scholarship**

- Presentation of Papers and Abstracts to Learned Societies and at National and International Symposia, Session Chairships, Published Proceedings
- Other presentations, local and recent CMEs
- Publications
  - Clinical trials research, clinical surveys and meta-analyses
  - Case studies of < 5 subjects and case reports
  - Reviews
  - Editorials
  - Letters to the Editor and other publications
  - Textbooks and Chapters in Textbooks
  - Other Publications

51-52

**Referees**

## GENERAL AND PERSONAL DETAILS

<b>Name</b>	Michael Edward Ellis
<b>Nationality</b>	British
<b>Date of birth</b>	8th July 1945
<b>Family</b>	Married to Dr Ulla Hedstrom, Consultant Infectious Diseases. Four children: Matthew, Emma, Clare, Michael
<b>Communications</b>	(+44) 7745973766 (+44) 1752 724178 <a href="mailto:mikeedwardellis@gmail.com">mikeedwardellis@gmail.com</a> The Lantern House Maristow House Roborough Plymouth PL6 7BZ
<b>Extra-professional interests</b>	Hill walking Scuba diving [NAUI Master Scuba Diver Certificate] Sailing [RYA Day Skipper Certificate] Theology, Christian Ministry Photography

## EDUCATION AND TRAINING

### SCHOOLS AND UNIVERSITY

Primary School : Laira Green , Plymouth	1951 – 1956
Secondary School : Devonport High School for Boys, Plymouth	1956 - 1963
University : St Catherine's College, Oxford	1963 - 1968
Medical School : Oxford University	1968 – 1972

### HONOURS AND AWARDS

School Chemistry Prize	1960
School Librarian	1961 - 1963
Medical Research Council Scholar	1967
Medicine-Gilliland Scholar	1983
Best externally funded Research Project UAE University	2003
Distinguished Performance Award, FMHS	2006
Winner, University Recognition Award for Excellence in Scholarship	2007
Award for top 10 cited Paper in European Journal of Cancer	2006-2008
Work of an exceptional standard for Portfolio in European Certificate of Essential Palliative Care	2012

### ACADEMIC EXAMINATIONS PRE-UNIVERSITY

General Certificate of Education 'O' levels: eleven subjects	1961
General Certificate of Education Advanced levels: Chemistry, Physics, Biology, Mathematics [Intermediate]	1963
General Certificate of Education Scholarship levels: Chemistry, Physics	1963

### PROFESSIONAL EXAMINATIONS, DEGREES, CERTIFICATES AND REGISTRATIONS

MA Biochemistry	1967
MSc [Research Biochemistry by thesis]	1968
BM BCh	1972
DRCOG	1975
Family Planning Certificate	1976
DCH	1976

MRCGP	1977
MRCP (UK)	1978
Specialist Certification in Internal Medicine, Infectious Diseases and Tropical Medicine [Royal College of Physicians of London JCHMT]	1984
FRCP Edinburgh	1989
FRCP London	1992
Specialist Register of European Specialist Medical Qualifications	1995
FRCP Glasgow	1998
FACP	2005
BA (First Class Honours), Theology, University of Gloucestershire	2011
European Certificate Essential Palliative Care	2012
GMC Registration	current
GMC revalidation	2014
Cyprus Medical Council Registration	current
Health Authority Abu Dhabi Registration and License to practise	2014-2016
Provisional Member Expert Witness Institute #8628	2014
Full Member Expert Witness Institute #8628	2020
Certificate completion Medico-legal Report Writing in Civil Claims [Professional Solutions]	2014
Diploma in Legal Medicine (DLM) (Pass with Distinction)	2023

## POSTGRADUATE MEDICAL EDUCATION AND APPOINTMENTS

House Surgeon, Gloucester Royal Infirmary	1973
House Physician Radcliffe Infirmary	1973
Family Medicine Trainee, Senior House Officer Emergency Medicine, Plymouth General Hospital	1974
Senior House Officer Obstetrics/Gynaecology, Paediatrics/SICU, Internal Medicine, Dorset County Hospital	1975 - 1976
Family Medicine Trainee, Dorchester	1976
Registrar in General Medicine, Cheltenham General Hospital	1977 - 1978
Registrar in General Medicine, Geriatric Medicine, Pulmonary Medicine, Cardiology, Infectious Diseases Aberdeen Teaching Hospitals	1978 - 1981
Senior Registrar in Infectious Diseases, General and Pulmonary Medicine, Regional Department of Infectious Diseases and Tropical Medicine, Monsall Hospital, University of Manchester School of Medicine	1981 - 1985



## PROFESSIONAL SENIOR APPOINTMENTS

Visiting Consultant in Paediatrics/Infectious Diseases, King Edward VIII Hospital, University of Natal, Durban	1982
Consultant Physician in Infectious Diseases, Regional Department of Infectious Diseases and Tropical Medicine, Monsall Hospital, University of Manchester School of Medicine	1985 - 1990
Consultant in Chest Medicine, Manchester Chest Clinic	1985 - 1990
Visiting Lecturer in Microbiology, Department of Bacteriology and Virology, University of Manchester School of Medicine	1985 - 1990
Consultant Physician and Acting Section Head of Infectious Diseases, King Faisal Hospital and Research Center, Riyadh, Saudi Arabia	1989 - 1990
Consultant Physician and Section Head of Infectious Diseases, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia	1990 - 1996
Associate Professor, King Faisal University, Dammam, Saudi Arabia	1990 - 1996
Head of Infectious Diseases, Consultant Infectious Diseases, Transplant Physician and Infection Control Physician, HCI International Medical Center, Glasgow, Scotland	1996 - 1998
Department Head of Medicine and Consultant Physician Infectious Diseases, Tawam Hospital, United Arab Emirates	1998 - 2000
Clinical Professor of Medicine, Faculty of Medicine and Health Sciences, United Arab Emirates University	1998 - 2000
Professor of Medicine, Faculty of Medicine and Health Sciences, United Arab Emirates University	2000 - 2010
Senior Consultant in Infectious Diseases and Tropical Medicine, Tawam Hospital	2000 - 2010
Consultant in Infectious Diseases and Tropical Medicine, Al-Ain Hospital	2003 - 2010
Consultant in Infectious Diseases and General Internal Medicine, Al-Ain Hospital	2005 - 2010
Chairman, Department of Medicine, Faculty of Medicine and Health Sciences, UAE University Medical School	2006 - 2010
Consultant Physician in Infectious Diseases and Internal Medicine, Evangelismos Hospital and Private Practice, Cyprus*	2011 - 2013
Consultant Physician in Acute Medicine and Infectious Diseases, Derriford Hospital, Plymouth, UK	2013 - 2014
Chief Internal Medicine Consultant Infectious Diseases, Ministry of Presidential Affairs Abu Dhabi, UAE; Consultant Infectious Diseases, Tawam Hospital, Al Ain, UAE	2014 - 2016

Freelance Expert Medical Witness in Internal Medicine  
and Infectious Diseases

2016 - current

*\*During this time I was also ordained for Christian Ministry in the Anglican Church, functioning as both Priest  
and Physician*

## MEDICO-LEGAL ACTIVITIES

Provisional Membership of The Expert Witness Institute	July 2017
Individual (Full) Membership of The Expert Witness Institute (MEWI)	September 2020
CPD (6 hours): Medico-legal Report writing in Civil Claims (Core skills)	October 2014
CPD (3.5 hours): Confidence in the Courtroom	October 2017
CPD (15 Credits): Maintenance of Infectious Diseases Certification	July 2022
CPD (6 hours): Bond-Solon Expert Witness Conference	November 2021
CPD (84 hours): UpToDate activities	2021-2022
CPD (6 hours): Bond Solon Courtroom Skills training Witness Familiarisation	September 2022
CPD (6 hours): Inspire MediLaw Annual Medico-Legal Conference	December 2022
CPD (18.5 hours): UpToDate activities	2023
CPD (1 hour): Webinar Expert Evidence Questions and Answers EWI	2023
CPD (2 hours): Experts Discussions and Joint Statements from Law to Practice EWI	2023
CPD (1 hours): Driven to drink FFLM	2023
CPD (16 CPD credits): Medicine 2023 (Royal Colleges Physicians UK)	2023
DLM (200 hours): Diploma Legal Medicine online study course	2023
Diploma in Legal Medicine Examination Pass with Distinction	2023
CPD (35.5 hours): UpToDate activities	2024
CPD (4.5 hours): BMJ e-learning, Abdominal Mass, COVID 19	2024
CPD (8 hours): Civil Proc Rules, GDPR, (Bond Solon, EWI)	2024
CPD (9 hours): Appraiser Training (MEDSU)	2024

## SAMPLE MEDICO-LEGAL CASES

CASE (C vs D)	CATEGORY	KEY CASE DETAILS	C/D/J
IR vs Hospital	Clinical Negligence	Mistaken diagnosis of pyelonephritis versus spinal epidural abscess leading to paraplegia, loss of earnings, social disability	C
JH vs Hospital	Clinical Negligence	Missed diagnosis lymphoma; treated as TB; patient death	C
MM vs UK Underwater firm	Industrial Compensation	Chronic HIV and HCV infection; alcohol liver disease; life expectancy	D
AJ vs NHS	Clinical Negligence	Mismanagement of invasive Candida infection in a neonate leading to severe disabilities	D
AC vs Local Authority	Medical Assessment	Multiple clinic-pathological conditions: fabricated or true	J
AM vs National Supermarket	Causation and compensation from Supermarket	Alleged Listeria myopericarditis from contaminated foodstuffs	C
LS vs UK Marine Services	Causation and negligence of the company	Developed falciparum malaria and neurological complications, on background of multiple sclerosis	C
CBW vs Waste Services Company	Causation and Industrial Compensation	Developed CMV infection from exposure to human waste	C
DF vs Infrastructure Company	Industrial Compensation, role of alcohol	Developed severe foot injury on background chronic alcoholism	D
JT vs Private Individual	Criminal	Assaulted by a work employee sustaining human bites and orthopaedic trauma and psychological injury	C
CM vs NHS	Causation	Question of missed diagnosis of rickettsial disease	C
AH/JC vs NHS	Clinical negligence	Missed diagnosis of systemic sepsis leading to death	C
BH vs mother	Causation	Non-accidental injury of child; salmonella potential cause for differential diagnosis of pathological long bone fracture	J
JB vs Crown Prosecution	Criminal	Chronic neglect leading to death from sepsis secondary to substantial skin ulceration	J
SO vs NHS	Clinical negligence	Inadequately managed case of COVID19; contracted in hospital; led to death of patient	C
AM vs NHS	Clinical negligence	Missed diagnosis and treatment of varicella zoster encephalitis leading to gross disability	C
JC vs Water Authority	Causation and compensation from Water Authority	Developed amoebic liver abscess from leakage of sewage into home	C
AS vs Health Services Ireland	Clinical negligence	Failure to diagnose visceral leishmaniasis in an HIV patient with lymphophagocytic histiocytosis	C
MK vs NHS	Clinical negligence	Failure to diagnoses and treat TB meningitis leading to death of claimant	C
YJ vs NHS	Clinical negligence	Delay in recognising sepsis and septic shock following ureteroscopic stone removal	C
AR	Causation, prognosis	TB acquired in a prison environment	C
CA vs Local Authority	Causation, prognosis	Rat infestation caused Giardiasis, immune deficiency, multiple psychiatric/medical problems and chronic fatigue	C
AB versus employer	Causation, prognosis	Developed group A streptococcal infection following work injury	C

C = claimant, D= defendant, J = joint

## GENERAL MEDICAL COUNCIL REVALIDATION ACTIVITIES

Designated Body	Faculty of Forensic and Legal Medicine (FFLM)
Responsible Officer	Dr Nigel Callaghan
Revalidation	Active: Registered with License to Practice
Next revalidation date	November 2024
Annual appraisals	Ongoing
Current appraisal	October 2023 (Summary Insert below)

<p><b>Domain 1: Knowledge, skills and performance</b></p> <p>Dr Ellis has submitted portfolio that is clearly reflective of his complete scope of work. He has demonstrated a very wide and diverse range in his area of work that requires high level of experience, skills, and expertise.</p> <p><b>Domain 2: Safety and Quality</b></p> <p>Dr Ellis has provided comprehensive supportive evidence reflecting and maintaining all areas of his practices. He has continued to maintained quality, safety, and delivery of high-quality services in his scope of work. Recent pass with Distinction in DLM examination suggest his continued efforts to learn and achieve high safety and quality in his work.</p> <p><b>Domain 3: Communication, partnership and teamwork</b></p> <p>A very good quality supporting information, and CPD activity has been achieved required for this appraisal cycle. A very good reflection that is continuing to enable Dr Ellis to maintain high professional and clinical standards.</p> <p><b>Domain 4: Maintaining trust</b></p> <p>Dr Ellis has provided very good supportive evidence with reflective notes where standards have been very well maintained. He continue to have his work reviewed by Peers or Legal firms instructing for Expert reports.</p> <p>No involvement in any significant event is reported for this appraisal.</p> <p><b>Appraiser's Declarations</b></p> <ol style="list-style-type: none"> <li>1. An appraisal has taken place that addresses the principles and values set out in Good Medical Practice. (YES/NO)</li> <li>2. There is no information been presented or discussed in the appraisal process that raises a concern about the Doctor's fitness to practise. (YES/NO)</li> <li>3. I confirm that the information presented within this submission is an accurate record of the documentation provided and used in the appraisal. I understand that I must protect patients from risk of harm posed by another colleague's conduct, performance or health. If I have concerns that a colleague may not be fit to practise, I am aware that I must take appropriate steps without delay, so that the concerns are investigated and patients protected where necessary. (YES/NO)</li> </ol> <p>Appraiser's Name: Dr Khalid Aziz Appraiser's GMC number: 5186298 Date of Appraisal: 28/10/2023</p> <p style="text-align: center;">3</p>	<p><b>Summary of Appraisal</b></p> <p>It was a pleasure to meet and have appraisal discussion with Dr Ellis again this year. I have recorded this appraisal in discussion and agreement with Dr Ellis and avoided any prejudice and bias. The appraisal discussion included the full scope of work. He provided and very comprehensive appraisal portfolio supported by good documentary evidence and reflection in relation to all four GMP domains. There appears to be no identifiable patient or third-party information. Dr Ellis has actively engaged throughout the entire appraisal process, including this appraisal discussion.</p> <p>We talked about Dr Ellis's general health and wellbeing, and he has been doing very well both physically and mentally.</p> <p>We discussed and recognised his last year's achievement, and it was a pleasure to know Dr Ellis worked hard in the last 6 months of the appraisal period and awarded a Pass with Distinction in the Diploma of Legal Medicine Examination. Dr Ellis reported preparing and passing the DLM examination was a very satisfying process. He reflected and acknowledged although this examination provides extraordinary knowledge in the field of Forensic and Legal Medicine but there were some elements that were perhaps foreign to his other areas of expertise. This certainly enabled him to maintain a very disciplined professional approach.</p> <p>Dr Ellis has been able to complete all but one element from his last year's PDP that is currently ongoing.</p> <p>We discussed and reflected on the challenges posed by the New Civil Procedure Rules (No. 35), accompanying practice direction that now requires Expert report to be no more than 20 pages. However, this has been robustly responded by Expert Witness Group and would be interesting to follow this through.</p> <p>We also had a very reflective conversation around suitability of some face-to-face clinical activity either as a in Specialist Infectious Diseases or Forensic Medicine. We recognised the current challenges and changes to the service deliver models and Forensic Medicine and within NHS. Given his vast knowledge, depth and breadth of experience, we explored other opportunities to work like Medical Examiner, GMC Tribunal Services, Medical Indemnity providers or perhaps considering some more senior role as a Non-Executive Director within NHS or other Health Related Organisations.</p> <p>We have discussed and developed SMART PDP objectives for next year. We have agreed that this will be evidence by the certificate of attendance and completions of courses and feedback.</p> <p style="text-align: center;">2</p>
---	--

Indemnity	Current 2023-2024
Data Protection	ICO registered 2023-2024
Safeguarding	Current 2024
Enhanced disclosure	Current 2024

## ACHIEVEMENTS

### ACCOMPLISHMENTS IN PREVIOUS POSTS IN THE MIDDLE EAST

#### 1: King Faisal Specialist Hospital and Research Center [KFSHRC], Riyadh, Saudi Arabia

*[The KFSHRC is the premier tertiary referral center in the Middle East, staffed by Western multinational medical staff, offering fully comprehensive care to Saudi nationals in a highly charged academic environment]*

- |   |             |
|---|-------------|
| Established the Kingdom's first HIV clinic with comprehensive multi-specialty support [counselling, community nursing etc] and educational services to a Western standard [summary and review in Ellis ME et al Saudi Med J 1993; 14: 325 – 333]. | 1989        |
| Established the Kingdom's first medical Hyperbaric Oxygen service [detailed in Ellis ME et al Saudi Med J 1995; 16: 319 – 325].   | 1990        |
| Expanded the Infectious Diseases services: clinically, Fellowship Training Programme, clinically orientated research activities in cancer medicine associated infections, EORTC collaboration.  | 1990 - 1996 |
| Organized and chaired a major international conference on AIDS [1300 delegates] venue Riyadh.   | 1994        |
| Programme Director Infectious Diseases Fellowship KFSHRC. During this time, five Saudi Residents entered the programme, two completed entirely locally and three completed in North America. All five are now Consultants in Saudi Arabia.        | 1990 - 1996 |

#### 2: HCl International Medical Center, Glasgow, UK

*[This is a privately funded tertiary care service with Middle Eastlinks providing world class Consultant led specialist medical care to global patients. It is the first hospital in the world to have introduced a fully electronic patient medical record and care system].*

- |  |             |
|--|-------------|
| Creation of an Infection Control service.  | 1996 - 1998 |
| Worked closely with Haematology service in providing infectious disease protocols, advice and Consultative service to the new International Blood and Marrow Transplantation Unit. | 1996 - 1998 |

#### 3: Tawam Hospital, Al-Ain, Abu Dhabi, United Arab Emirates

*[UAE tertiary referral hospital]*

- |  |             |
|--|-------------|
| The major goal was to remodel the Department of Medicine, to develop and foster academia. Goals were achieved particularly in establishing academic-orientated morning reports, cross boundary collaborations eg clinico-radiology meetings, | 1998 - 2000 |
|--|-------------|

in-house CME activities, educationally driven mortality reviews. An MRCP part 2 course was introduced with collaboration from Al Ain Hospital. A comprehensive Department manual was published incorporating organizational details, clinical practice guidelines, internal policies and procedures etc]. The Department has since attained accreditation by the Arab Board for Residency Training in Internal Medicine.

#### **4. Faculty of Medicine and Health Sciences, UAE University**

*[The UAE Federal University Medical School with focus on Undergraduate training and Basic and Clinical Research]*

A seamless transition from my post at Tawam Hospital to FMHS occurred in 2000, first as full Professor and then in 2006 as appointed Chair, Department of Medicine. This permitted the following achievements:

Developing and successfully seeking accreditation of the FMHS in collaboration with Tawam and Al-Ain Hospital for Residency Training in Internal Medicine [Arab Boards]. 2002

Establishing close links with the Royal Colleges of Medicine of the UK, through my appointment as International Advisor. A particular outcome was to form an MRCP[UK] clinical examination [PACES] centre at Al-Ain Hospital. Regular diets are firmly established; local UAE physicians are trained to function as MRCP[UK] examiners. 2004

Through my ties with the EORTC, Tawam Hospital's Hematology Unit became recognized and accredited by the EORTC as a clinical trials center [EORTC center #8101]. There have been several successful studies undertaken in collaboration with non-Faculty colleagues and colleagues from faculty basic sciences, leading to high quality publications (eg Lancet, 2003, Clin Infect Dis, 2001, Clin Immunol, 2006). 2000-

Chairing the first cross boundary, Al-Ain Medical District Human Research Ethics Committee, to implement high quality review process of all projects involving human subjects. The Committee achieved formal international recognition as a Review Body. 2003-2007

Working with colleagues in FMHS and Al-Ain Hospital to establish the UAE's first dedicated clinical teaching and research Unit, the Professorial Medical Unit. This enhances patient care, fosters undergraduate and postgraduate training programmes and acts as a resource for clinical research. 2008

**5. Consultant in Infectious Diseases, Ministry of Presidential Affairs, Abu Dhabi and  
Consultant in Infectious Diseases, Tawam Hospital, Al Ain**

I was privileged to work as a senior Consultant member of an International Medical team supporting the health of a leading VIP of the UAE. This involved daily clinical and administrative duties and consultations with colleagues.

In addition I provided infectious disease consultations on request to VIPs at Tawam Hospital.



## MEMBERSHIP OF LEARNED SOCIETIES

Member, British Infection Society	1981 - 2000
Member, British Thoracic Society	1981 - 1992
Member, American Society of Microbiology	1992 - 2010
Fellow, Manchester Medical Society	1981 - 1992
Fellow, Infectious Diseases Society of America [by merit]	1994
Member, Immunocompromised Host Society	1985 - 1988
Member, European Undersea Biomedical Society	1990 - 1996
Member, Undersea and Hyperbaric Medical Society [by merit]	1990 - 1996
Member, Invasive Fungal Infections Co-operative Group, European Organisation for Research and Treatment of Cancer (EORTC) [by merit]	1991 - 2010
Member, International Antimicrobial Trials Group, EORTC	2000 - 2002
Member, European Society Clinical Microbiology Infectious Diseases	2010
Member (Full) Expert Witness Society	2020
Associate Member Faculty Forensic and Legal Medicine (DLM)	2023

## SPECIAL CLINICAL EXPERIENCE

- Training in the use of the Trexlar Unit for management of patients with viral haemorrhagic fever
- Hyperbaric Medicine
- Tropical Medicine
- HIV
- Invasive fungal infections
- Bronchoscopy
- Differential diagnosis and management of pulmonary and extra-pulmonary TB
- Legal Medicine

## RESEARCH ACTIVITIES

### RESEARCH INTERESTS

- Infections in the immunocompromised host
- Invasive mycoses, particularly invasive aspergillosis
- Antifungal antimicrobials
- Respiratory infections
- The clinical trial

### SELECTED RESEARCH ACTIVITIES AND PROJECTS

#### **Histone synthesis in the neonatal rat model**

1967 - 1968

developed an in vivo system using the neonatal rat brain to study the role of phosphorylated histones in cellular differentiation. This involved the use of nuclei fractionation techniques, electron-microscopy and autoradiography.

Working under Professor Sir Hans Krebs and Dr Lloyd Stocken, Oxford University as an MRC Scholar the work led to a thesis (MSc).

#### **Controlled clinical trials of interferon treatment of chronic hepatitis C in patients on haemodialysis**

1990 - 1993

Studies performed in collaboration with nephrology and gastroenterology colleagues at KFSHRC, Saudi Arabia, an area of extremely high endemicity for chronic HCV, and the commonest mode of death in patients with chronic renal failure.

#### ***Liposomal amphotericin B in invasive aspergillosis EORTC # 19923***

1992 - 1998

This was a major study by the Invasive Fungal Infections Group of the EORTC, in that this European Group took the lead in performing the first ever, multicentered randomized prospective clinical efficacy study of antifungals. I was selected to be Principal Investigator among 18 centers, with responsibility for trial design, leading data interpretation, writing, publishing and presenting the results.

#### **Meta-analysis of fungal endocarditis**

1996 - 2000

A major in depth definitive epidemiologic review and statistical assessment of outcome of fungal endocarditis in a 30 year span of published literature. Performed in collaboration with the Biomedical and Research Center, KFSHRC, Riyadh.

A clinical study to examine the efficacy and tolerability of human recombinant interleukin-11 to prevent sepsis when given as adjunctive therapy to hematologic patients with leukemia undergoing induction or consolidation chemotherapy. 2001 -2005

A recently concluded multi-departmental, international collaborative, placebo-controlled double-blinded clinically based study. Funded Terry Fox Grant # 2000/03.

#### **Development of a clinical trials research unit [CTRU]**

2000 -2002

As part of ongoing collaboration with Tawam Hospital, and in fostering both cross boundary relations of FMHS/MOH and clinical-science interests, I have established the nucleus of a CTRU. This is centered in the Hematology Division at Tawam. It has the following components: EORTC accreditation as a clinical trials center [Center # 8101], grant funded Research Committee approved projects running [which include controlled clinical trials], recent appointment of a clinical research nurse specialist, a part-time voluntary research physician and full collaboration and support of Hematology colleagues and of FMHS colleagues in Immunology/Microbiology.

### **CLINICAL RESEARCH AWARDS AND GRANTS**

Medical Research Council Scholarship 1967 - 1968

Medicine-Gilliland Travelling Fellowship to King Edward VIII Hospital, Durban, for clinical experience/research in paediatrics 1983

A study of interferon in chronic hepatitis C: Roche 1992 - 1993

A study of fluconazole prophylaxis in neutropenic patients : Pfizer 1993 - 1994

Comparative dosing study of liposomal amphotericin B: EORTC 1994 - 1998

Study of staphylococcal toxins: Merck, Sharp and Dome 1999

A study of Neumega in leukemic patients: Wyeth-Lederle 2000

A prospective clinical trial of recombinant interleukin-11 to prevent sepsis in leukemic patients: Terry Fox 2001 - 2003

A prospective fungal serology study in leukemic patients: UAE FMHS grant 2001 - 2003

Bacteremia in leukemic patients: Wyeth Lederle 2002 - 2004

Liposomal amphotericin B in neutropenic fever: Gilead Sciences 2004

Antifungal therapy, safety + efficacy (Caspofungin): MSD 2004

### **TEACHING ACTIVITIES**

*Dr Michael Ellis Full CV 2024*

## SUMMARY OF PREVIOUS TEACHING ACTIVITIES

<b>National UK Examination Boards</b> Marking written GCEs and GCSEs in Human Biology	1967 - 1969
<b>University of Aberdeen</b> Ward based clinical teaching to medical students	1978 - 1981
<b>University of Manchester</b> Bedside clinical teaching and didactic lectures at Regional Department of Infectious Diseases and Tropical Medicine; teaching at Liverpool School of Tropical Medicine's DTM course; MRCP lecturer at University of South Manchester; postgraduate CMEs to Community Physicians and General Practitioners; community lectures in HIV.	1981 - 1990
<b>King Faisal Specialist Hospital &amp; Research Center, Riyadh</b> Director Infectious Diseases Fellowship Programme; Chairman Fellowship Training Committee; Participation in Internal Medicine Teaching activities; External examiner final Medical Examinations, King Faisal University, Dammam.	1990 - 1996

## UNDERGRADUATE TEACHING ACTIVITIES AT FMHS 2000-2010

### Classroom Specified Lectures, Demonstrations, Seminars

#### Clinical Skills module OSC:

Record writing  
History and Physical of Respiratory system  
Bedside clinical teaching Hematology/Immunology  
Comprehensive history taking Respiratory system Integrated  
History and Physical of Gastrointestinal system

#### Multidisciplinary seminars:

Diagnosis and follow up of chronic inflammatory and immunologic diseases  
Septic arthritis

Community acquired pneumonia

Fever

Human Immunodeficiency Virus disease

#### Musculoskeletal module:

Bacterial bone infections [OA10]  
septic and bacterial arthritis [OA20]  
Muscle and nerve infections [N9]

#### Cardiovascular module:

Pericardial diseases [AHD9]  
Myocarditis and cardiomyopathy [AHD10]

#### Haematology-Immunology module:

Infections in the immunocompromised host [IMM2:18]  
Blood transfusion infections [IMM1:19]

#### Respiratory system module:

Fungal and chronic lung infections  
Pneumonia

### Communication skills for Medical Sciences year 02

#### Medical Sciences Course Unit 10:

Principles of Infection  
 General mycology  
 Invasive fungal diseases  
 Teaching Classroom FMHS/HCT BSc Program in Medical Laboratory Technology

#### **Ward-bedside**

##### Junior Medical Clerkships

Morning reports  
 Teaching ward rounds Al Ain Hospital  
 End of rotation MCQs, vivas, clinical evaluations

##### Senior medical Clerkships

Faculty rounds at Tawam Hospital  
 Clinical seminars  
 End of rotation MCQs, vivas, clinical evaluations

#### **Organisational**

Supervision of student elective project on bacteremia  
 Co-supervision of student project on Pneumonia  
 Co-Director Final Integrated Examination of Clinical Sciences UAE University (2000-2004)  
 Director Final Integrated Examination of Clinical Sciences UAE University (2004-2007)  
 Coordinator Written Paper Final Integrated Examination of Clinical Sciences UAE University (2000-2006)

#### **Postgraduate Teaching activities at FMHS 2000-2010**

Residency Training in Internal Medicine: bedside and classroom teaching  
 External examiner MRCP[UK]  
 Lecturer BSc Program in Medical Laboratory Technology FMHS/HCT 'Biology of Disease'

## ADMINISTRATIVE/COMMITTEES

### UNITED KINGDOM

Organizing Secretary of the National Caring for AIDS Conference, Manchester	1987
Organizing Secretary of the National Caring for AIDS Conference, London	1988
Clinical Member of Control of Infection Team, Monsall Hospital Manchester	1988
Member of General Subcommittee, North West Regional Health Authority, Manchester	1988
Member of Monsall Hospital Medical Division, Manchester	1984 - 1989
Chairman, Control of Infection Committee, HCI International Medical Center Glasgow	1996 - 1998
Member, Bone Marrow Transplant Team, HCI International Medical Center, Glasgow	1996 - 1998
Member EORTC. Invasive fungal Diseases Investigation Group, EORTC, Brussels	1993
Member, Ethics Committee, HCI International Medical Centre Glasgow	1997 - 1998

### SAUDI ARABIA [KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER]

Member of Infection Control Committee	1991- 1996
Member of Bone Marrow Transplant Committee	1991- 1995
Member of Adhoc Gulf War Germ Warfare Committee	1991
Member of Adhoc INAH Chemoprophylaxis Committee	1991
Chairman of Fellowship Training Committee	1992 - 1996
Chairman of Adhoc Fungal Study Group	1992 - 1995
Chairman of Adhoc AIDS Committee	1992
Member of Adhoc Committee Occupational Exposure to Infectious Diseases	1992
Member of Transplantation Committee	1992 - 1993
Member of Department of Medicine Publications Committee	1992 - 1994

Member of Adhoc Penicillin Skin Testing Committee	1992
Member of Postgraduate Education Committee	1992
Member of Clinical Protocol Committee	1993 - 1994
Member of Clinical Research Committee	1995 - 1996
Member of Selection Committee, King Faisal International Prize in Medicine	1993
Member of Liver Transplant Committee	1992 - 1993
Member of Organizing Committee for Infectious Diseases	1992
Chairman, Organizing Committee. Second International Conference on AIDS -Saudi Arabia	1994
Chairman, OSHA Guidelines (TB) Review Committee	1994
Member, Liver Transplant Unit	1994 - 1996
Member, Hickmann Working Group	1995
Member, EORTC Invasive Fungus Group, Brussels	1992 -
Section Head, Infectious Diseases	1990 - 1996
Fellowship Program Director, Infectious Diseases	1992 - 1996
Chairman, Fellowship Committee, Department of Medicine	1991 - 1996
Acting Chairman (rotating), Department of Medicine	1992 - 1996
Director of Hyperbaric Medicine service	1992 - 1996
Acting Chairman, Clinical Protocol Committee	1993
Coordinator for Mortality and Morbidity, Department of Medicine	1993
External Examiner, Final MB Exam and King Faisal University Fellowship, King Faisal University, Dammam	1993
External Examiner, Final MB Exams, King Saud University, Riyadh	1992
Member, Research Advisory Council	1995

**UNITED ARAB EMIRATES: TAWAM HOSPITAL**

Head of Department of Medicine	1998 - 2000
Chairman, Pharmacy and Therapeutics Committee	1998 - 2001
Member Infection Control Committee	1998 - 2000
Member Faculty of Medicine and Health Sciences University Council	1998 - 2000
Chairman Antimicrobials Use Committee	1999
Member Research Committee	1999
Co-chair, Faculty of Medicine and Health Sciences Resources Evaluation Committee	1999
Co-coordinator Senior Medical Clerkship Faculty of Medicine and Health Sciences	1999
Member Outpatient services committee	1999

**UNITED ARAB EMIRATES: FACULTY OF MEDICINE AND HEALTH SCIENCES**

Chairman FMHS Committee of Enquiry on alleged inappropriate examination conduct	2000
Chairman Committee to review Health and Safety Issues of Students in Clinical settings	2000
Member Tawam Hospital Research Review Committee	2001 -
Chairman Ministry of Health Committee of Enquiry on Physician care	2001
Chairman Ministry of Health Committee of Enquiry on Pharmacy Services at Tawam Hospital: drug procurement, storage and inventory	2001
Co-chair Steering Committee on Evaluation FMHS # financial Resources, general facilities, Library and other computer resources	2000
Member Abu Dhabi Health Authority Pharmacy and Therapeutics Committee	2001
Member Promotions Committee	2000 -
Member Subcommittee Promotions for Service Guidelines Review	2003
Member Organising and Scientific Committees, 4 <sup>th</sup> International UAE Cancer Conference, Abu Dhabi	2001
Member Sheikh Khalifa/Tawam/Mafraq Hospitals Collaborative Cancer Committee	2000



Member interview group for student applicants to FMHS	2000
Member Pharmacy Curriculum Review Group	2001
Member Review Committee Multi-disciplinary Seminars	2001
Member Teaching Assessment sub-committee of the Curriculum Committee	2001
Member Strategic Review Committee on Education	2001
Member Committee on Medical training	2001
Member Search Committee Chair Biochemistry	2001
Member Interview Committee Professor Virology	2001
Director Arab Board Program Internal Medicine	2001 - 2004
Deputy for Acting Chairman Medicine at intervals	2000 - 2004
Member Scientific Committee The 2 <sup>nd</sup> Al Ain International International Immunology meeting	2001
Chairman Committee on Protection and Treatment of Aspergillosis in Tawam Hospital	2001
Founder Member of the Intercity Infectious Diseases/Microbiology Group and Chairman	2002
Member UAE National Tuberculosis Control Committee, Ministry of Health	2002 - 2008
Member UAE National Antibiotics Committee, Ministry of Health	2002 - 2007
Member of Terry Fox Grants Research Awards Committee, UAE University	2002
Member of Medical Students Application Interview Committee, UAE University	2001 - 2004
Acting Chairman Tawam Hospital Research Review Committee	2002
Chairman Tawam Hospital Research Review Committee	2002 - 2004
Member Search Committee Assistant Professor Microbiology	2003
Member Search Committee Associate Professor Paediatrics	2002
Member working group for Recruitment/Resource Planning In Clinical Microbiology, Immunology and Infectious Diseases	2003

Chairman Postgraduate Education Committee	2002 – 2007
Member Education Advisory Board	2002 – 2007
Organiser and Chair of Conference on Update in Infectious Diseases, UAE University	2003
Member Human Research Ethics Committee Planning Group	2003
Member Infections Control Committee, Al Ain Hospital	2004
Chairman, Al Ain Medical District Research Ethics Committee	2003 – 2007
Member Organising Committee 4 <sup>th</sup> GCC Medical Education Conference	2004
Member Organising Committee Conference Emerging Infectious Diseases	2004
Member Selection Committee for the 4 <sup>th</sup> Sheikh Hamdan International Awards 2006	2005
Member FMHS Promotions Committee	2007
Member Infection Control Committee, Al Ain Hospital	2008-2009
Member Organising and Scientific Committees, 3 <sup>rd</sup> Al Ain International Immunology Meeting.	2008
Chair, Finance Committee, 3 <sup>rd</sup> Al Ain International Immunology Meeting.	2008

## INTERNATIONAL ACTIVITIES

### INTERNATIONAL MEDICAL JOURNALS REVIEWER

Journal of Infection

Clinical Infectious Diseases

Journal of Veterinary Mycology

Saudi Medical Journal

Annals of Saudi Medicine

Journal of Family and Community Medicine

Infection

Emirates Medical Journal

ISRN Immunology

### INTERNATIONAL GROUPS

Member-participant of Expert Panel on Invasive Fungal Infections, Annency, France	1999
Member of Invasive Fungal Infections Co-operative Group of the European Organisation for Research and Treatment of Cancer [EORTC]	1994 - 2010
Member of International Antibiotics Trial Group of the EORTC	2000
External Examiner for PACES MRCP[UK]	2002 - 2010
Corresponding Editor International Journal Infectious Diseases	2002 – 2010
Member International Board, Mediterranean Congress on Chemotherapy	2004
Member International Advisory Panel in Kumar and Clarke's Clinical Medicine	2005 - 2010
External Examiner to the Arab Boards in Internal Medicine	2005 – 2010
Member EORTC Working Party on Growth Factors in Cancer	2005

## SCHOLARSHIP

### PRESENTATION OF PAPERS AND ABSTRACTS TO LEARNED SOCIETIES AND AT NATIONAL AND INTERNATIONAL SYMPOSIA, PUBLISHED PROCEEDINGS AND SESSION CHAIRSHIPS.

[\* = presented in person and principal author ]

Oxprenolol-hydrallazine interactions: British Pharmaceutical Society, London	1981
*Hyperbaric oxygen in anaerobic infections: The British Society for the Study of Infection, Edinburgh	1982
*The Role of Hyperbaric Oxygen Therapy: The 1st International Conference of Infection Control, Harrogate	1984
*Causes of Diarrhoea - A Regional View: The British Society for the Study of Infection, London	1984
*Cardioselectivity of atenolol in asthmatic patients: The Joint British Thoracic Association/Thoracic Symposium London	1981
*Atenolol and Metoprolol interactions with cimetidine in asthmatic patients: International Pharmacology Symposium, Munich	1983
*Cardioselectivity of atenolol in relation to dose: 8 <sup>th</sup> Scientific meeting International Society of Hypertension, Milan	1983
*Diarrhoea in Adults and Children: International Congress for Infectious Diseases Cairo	1985
Streptococcal pyogenic septicaemia in North Manchester: British Society for the Study of Infection, Lake District	1985
Amodioquine induced Agranulocytosis: Suppression of Granulopoietic Differentiation <i>in vitro</i> by a metabolite but not the parent drug. British Society of Haematology.	1986
*Chickenpox in Adults: Smoking and Pneumonia: British Society for the Study of Infection	1987
*Presentation of papers on respiratory tract disease and other aspects of HIV infection: Caring for AIDS Multidisciplinary Conference, Manchester	1987
*Presentation of papers on respiratory tract disease and other aspects of HIV infection: Caring for AIDS Multidisciplinary Conference, London	1988
*Typhoid Fever in Black South African Children, International Conference of Infectious Diseases, Rio de Janeiro, Brazil	1988
*Use of Interferon in HIV Positive Subjects, Cancer Congress, UAE	1989

Influenza Vaccination in Adults with Cystic Fibrosis, British Thoracic Society, London	1989
*Update on Antimicrobial Agents to the Annual Pathology Symposium King Faisal Specialist Hospital and Research Center, Riyadh.	1989
*New Modalities of Treatment of Infections in AIDS to the 2nd Annual Symposium on Advanced Medicine, Riyadh Military Hospital, Saudi Arabia	1989
*Renal transplantation Associated HIV Infection in Saudi Arabia – Global Overview : British Society For the Study of Infection, Manchester	1990
*A study of rapid vs. slow infusion rates of amphotericin B on toxicity, tolerance and efficacy, ICAAC 31st Conference, Chicago	1991
*In vitro susceptibility of <i>Brucella melitensis</i> to the new quinolone PD127391 in comparison with other antimicrobial agents, ICAAC 31st Conference, Chicago	1991
*Chronic NANB hepatitis complicated by renal failure, treated with recombinant interferon. 5th International Conference on Viral Hepatitis, Madrid	1992
Renal transplantation with HIV infection - Saudi Arabian experience 2nd Congress Arab Society Nephrology and Renal Transplantation, Cairo	1992
*Treatment of chronic hepatitis C with interferon in patients on haemodialysis. 4th Saudi Hepatogastroenterology Symposium, Riyadh	1993
Treatment of histologically advanced chronic hepatitis C with IFN : double blind placebo controlled study. 4th Saudi Hepatogastroenterology Symposium, Riyadh	1993
*Fluconazole prophylaxis for fungal infections in neutropenic patients. Symposium on advances in the diagnosis and management of Infectious Diseases, Jeddah, Ministry of Health	1993
Risk factors for HCV infection in patients attending a polyclinic : Symposium on Advances in the Diagnosis and Management of Infectious Diseases, Jeddah, Ministry of Health	1993
HCV infection in patients attending a polyclinic : International Symposium on Clinical Epidemiology, Cairo	1993
*Fungal infections in cancer patients. 1st Middle East Congress on Oncology, Beirut	1993

- Chronic hepatitis C treatment by recombinant  $\alpha$ IFN in patients on hemodialysis. American Society of Nephrology : Baltimore 1993
- HCV RNA response to IFN a therapy of chronic hepatitis C. American Society for the Study of Liver Disease, Boston 1993
- Nested polymerase chain reaction applied in search for . HIV-1 DNA from sero-indeterminate Saudi Arabian blood donors. International Society of Blood Transfusion Congress in Barcelona, Spain 1993
- \*Fluconazole prophylaxis in haematological patients with neutropenia. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans 1993
- \*Fluconazole prophylaxis for fungal infections in neutropenia. Trends in Invasive Fungal Infections II, Manchester 1993
- Kidney transplantation after successful therapy with interferon  $\beta$  in hemodialysis patients with HCV. 26th Annual Meeting, American Society Nephrology 1993
- Kidney transplantation after successful therapy with interferon  $\beta$  in hemodialysis patients with HCV. 3rd Congress of Arab Society of Nephrology and Renal Transplantation, Riyadh 1993
- Invasive fungal infection in Saudi patients with malignant haematological disease. Saudi Oncology Symposium, Riyadh 1994
- \*Respiratory tract manifestations of HIV. 2nd International AIDS Conference, Saudi Arabia 1994
- \*Challenges of fungal disease in the immunocompromised host. Saudi Oncology Symposium 1995
- \*Randomised multicentre trial of 1mg/kg versus 4mg/kg Liposomal Amphotericin B in the treatment of invasive Aspergillosis. EORTC Protocol 19923, ICAAC, New Orleans 1996
- Risk factors and outcome from invasive Aspergillosis. ICAAC. New Orleans 1996
- \*Invasive Aspergillosis treated with high/low dose liposomal amphotericin B. Spanish Society of Haematology, Malaga 1996
- \*Liposomal amphotericin B in the treatment of invasive aspergillosis Supportive care in Cancer (9th International MASCC Symposium) St Gallen, Switzerland 1997

- \*Management of acute invasive aspergillosis. 1997  
Trends in Invasive Fungal Infections 4. Barcelona
- \*Fungal endocarditis – the evidence in the world literature 1999  
1965 – 1995. Trends in Invasive Fungal Infections 5. Malta
- \*Lipsomal amphotericin B treatment of invasive aspergillosis - 1999  
dosage issues. American Society of Hematology  
[satellite symposium]. New Orleans
- \*Moving targets, evolving therapeutics, failures and aspirations - 2001  
where are we going in cancer infection. 4<sup>th</sup> International  
Cancer Conference, Abu Dhabi
- Interferon  $\alpha$  for chronic hepatitis C in hemodialysis patients - 2000  
a randomized prospective controlled study. American Society of  
Nephrology.
- \*Fungal Endocarditis. 1<sup>st</sup> International Conference on Infectious 2000  
and Tropical Diseases. Oman
- Emerging fungal infections in the immunocompromised host. 2000  
Implications for therapy. Conference on challenges of emerging infections.  
University of Kuwait
- \*Invasive aspergillosis in non-compromised patients: paradigm of 2000  
antimicrobial management, adjunctive treatments and pathogenesis.  
EORTC IATG working group, Genoa.
- Randomised controlled trial of Interferon  $\alpha$  in patients with chronic 2000  
Hepatitis C on haemodialysis. Alfuryah, O., Ellis M., et al.  
XXXVII Congress of the European Renal Association, European  
Dialysis and Transplant Association, Nice, France.
- Chronic invasive rhinocerebral aspergillosis in a clinically 2001  
Immunocompetent patient. IFOS World ENT Conference, Cairo
- \*Invasive fungal infections: evolving challenges in diagnosis and 2001  
therapeutics. Plenary session. The second Al Ain International  
Immunology meeting, UAE
- \*Management of fungal complications in leukemia in 2001  
immunocompromised patients. Plenary Speaker. International Society  
of Hematology, Cairo

- Long-term follow up of haemodialysis patients with chronic hepatitis C Infection – favourable outcome with  $\beta$ -interferon followed by kidney transplantation. Abstract M221. XXXVIII Congress of European Renal Association, European Dialysis and Transplant Association. Vienna, Austria. 2001
- \*A combined approach of early chest CT scanning and Liposomal amphotericin B treatment is associated with a high clinical response rate and low mortality in leukemic patients neutropenic from chemotherapy who have invasive pulmonary aspergillosis. American Society of Hematology, Orlando 2001
- \*Liposomal amphotericin B in the treatment of Invasive Aspergillosis in Neutropenic patients. Invited speaker. The Hong Kong Society of Haematology . Hong Kong. 2002
- \*Invasive Mycoses: meeting the Challenge. Invited speaker. The Taiwan Society of Hematology. Taiwan. 2002
- \*Candidemia 1995 – 2001 in a tertiary care hospital of the United Arab Emirates. European Confederation of Medical Mycology, Budapest 2002
- \*Prevention of bacterial infection by recombinant human interleukin-11 in patients with hematological malignancy undergoing chemotherapy: results of a prospective double-blind placebo-controlled randomized clinical trial. American Society of Hematology, Philadelphia 2002
- \*Diagnosis of invasive fungal infections: a clinical perspective. Invited speaker and workshop. Dead Sea, Jordan. 2002
- \*Management of aspergillosis. Invited speaker. 29<sup>th</sup> Turkish Society of Hematology Congress. Antalya. 2002
- Reduced clearance of IFN $\beta$  in ESRD patients with HCV on Haemodialysis. XXXIX Congress of the European Renal Association European Dialysis and Transplant association. Copenhagen, Denmark. 2002
- \*Diagnosis of invasive fungal infections: a clinician's perspective. Invited speaker. Dubai workshop. 2003
- \*Role of liposomal amphotericin B in invasive pulmonary aspergillosis. Invited speaker 5<sup>th</sup> Turkish National Neutropenia symposium, Antalya. 2003
- \*Management of invasive fungal infections. Guest speaker Australia. 2003
- \*Approaches to diagnosis and management of haematological patients with Invasive mycoses. Invited speaker. Karpenessi, Greece. 2003



- \*Reduction of bacterial infection in patients with haematological malignancy by rhIL-11. 4<sup>th</sup> Annual UAE University Research Conference 2003
- Predictive factors of poor outcome in hospitalized patients with pneumonia: a retrospective analysis of 314 cases from Tawam Hospital  
5<sup>th</sup> Annual UAE University Research Conference 2004
- \*Emerging fungal infections in the Mediterranean area 14<sup>th</sup> Mediterranean Congress of chemotherapy and 3<sup>rd</sup> Pancyprian Congress of Chemotherapy and Infectious Diseases, Limasol, Cyprus 2004
- \*Treatment options for Invasive Aspergillosis. Invited speaker. Finish Haematology Association, Helsinki 2005
- \*Association between the serum chemokine RANTES, platelets and infection in patients with haematological malignancy. 6<sup>th</sup> Annual UAE University Research Conference, Al Ain UAE. 2005
- \*Changes in the leucocyte trafficking chemokine RANTES in patients with haematological malignancy. International Conference on Emerging Infectious Diseases, Al Ain, UAE 2005
- \*New insights into the management of invasive fungal infections. Kuwait University. 2005
- \*The role of azoles in managing invasive fungal infections. Kuwait Institute for Medical Specialization. 2005
- \* Modulation of the systemic inflammatory response by human interleukin-11A prospective randomized placebo controlled clinical study in patients with Acute myeloid or lymphoblastic leukemia and non-Hodgkin's lymphoma. FOCIS, San Francisco. 2006
- \*Challenges in the management of febrile neutropenia. 7<sup>th</sup> Febrile Neutropenia Symposium, Ankara, Turkey. 2006
- \*Invasive Fungal Infections. Federation of Royal Colleges of Physicians, UK. International Conference Al-Ain. 2006
- \*\*Intermittent dosing strategy for empiric therapy with liposomal amphotericin B. Conference on New Insights, New Data, New Challenges in Invasive Fungal Infections. Rome, Italy. 2006

- \*Infections in patients with Cancer: Febrile Neutropenia.  
International Conference Recent Advances in Clinical Oncology.  
Al-Ain, UAE. 2007
- \*Standard dosing (3mg/kg/day for 14 days) versus Intermittent High dosing  
(10mg/kg day 1, 5mg days 3, 5) of liposomal amphotericin B for treating  
febrile neutropenia: a comparative prospective clinical trial of safety, efficacy  
and kinetics.  
8<sup>th</sup> Congress of the European Association for Clinical Pharmacology and Therapeutics.  
Amsterdam. 2007
- \*Fungal endocarditis.  
Guest speaker, 3<sup>rd</sup> Trends in Medical Mycology. Torino, Italy. 2007
- Chair Workshop 12, Focal Fungal Infections. 3<sup>rd</sup> Trends in Medical  
Mycology. Torino, Italy. 2007
- \*New dosing strategies in High Risk Patients.  
EBMT Satellite Symposium, Lyon, France. 2007
- \*Management of febrile neutropenia.  
Plenary Speaker. 1<sup>st</sup> Emirates Hellinic Medical Conference. Dubai, UAE. 2007
- \*Emerging strategies for Invasive Fungal Infections.  
Satellite Symposium at the 6<sup>th</sup> International Conference on Antimicrobial  
Agents and Resistance. Singapore. 2007
- \*TB: Clinical Orientation and UAE Focus.  
Clinical workshop on TB. 3<sup>rd</sup> Al Ain International Immunology Meeting. 2008
- Chair Plenary Symposium Inflammatory Markers in Infection, sepsis  
and Septic shock, 3<sup>rd</sup> Al Ain International Immunology Meeting. 2008
- Randomized trial of 10-5-5 mg/kg vs. daily standard dose liposomal  
amphotericin B for neutropenic fever. ICAAC. 2009

## OTHER PRESENTATIONS, LOCAL AND RECENT CMES

[\*presented in person ]

*Diagnosis and management of fungal infections in the immune-compromised host. Guest lecturer, Roche Research Institute, Basel	1992
*Research methods in clinical medicine. Mini-symposium King Faisal Specialist Hospital and Research Center, Riyadh	1992
*Update in the management of fungal infections in the immune compromised host. Guest lecturer, Kuwait	1993
*Update in the management of fungal infections in the immune compromised host. Guest lecturer, United Arab Emirates	1993
*Challenges in the management of systemic fungal infections. Guest lecturer, ARAMCO, Saudi Arabia	1995
Chairperson Workshop on Hospital Infections. Dubai	1999
*Hospital acquired pneumonia – update CME for Registered Pharmacologists, UAE	2001
*Infections in the immunocompromised host – update CME for Registered Pharmacologists, UAE	2001
*Infection prevention in cancer patients. CME update for nurses Oncology workshop, Tawam	2000
*Viral hepatitis. CME for Primary Care Physicians. Al Ain	2001
*Sino-cerebral aspergillosis. CME for microbiologists, Tawam	2000
*Neutropenic fever. CME to Hematology staff, Tawam	2000
*Emerging fungal pathogens. Implications for treatment. CME Tawam Hospital	2000
*Management of antibiotic resistant neutropenic fever and invasive aspergillosis. Guest lecturer, Beirut	2001
*Chairman Symposium on Antibiotic resistance in the hospital setting Dubai, UAE	2001
*Chairman session on Clinical and Therapeutic aspects of Intestinal pathogens: Clinical Infectious Diseases CME FMHS, UAE University	2001
*Chairman Plenary session Infections in malignancies. 4 <sup>th</sup> UAE International Cancer Conference, Abu Dhabi	2001
*Bioterrorism: Al Ain Medical District	2001

* Pulmonary fungal infections in the immunocompromized host. Annual Workshop in Asthma, Allergy and Pulmonology. FMHS	2002
*Emerging infections – update. At Update in Internal Medicine CME. FMHS.	2002
*Invasive fungal infections. At Update in Internal Medicine CME. FMHS.	2002
Chair, session at Update in Internal Medicine CME. FMHS.	2002
*New advances in Invasive Fungal Infections Management. Al-Ain	2003
*Non-antibiotic approaches to the management of Infectious diseases. At Update in Infectious Diseases symposium, FMHS.	2003
*Sepsis and multiple organ damage: pathophysiology and management. Update in Nephrology, FMHS	2004
*Invasive fungal infection. Al-Ain Hospital CME.	2005
*Management of Invasive fungal infections. Tawam Hospital CME.	2005
*Aspergillosis and Mucormycosis: Differential diagnosis and Treatment. Dubai.	2007

## PUBLICATIONS

### Clinical trials research, clinical surveys and meta-analyses

Cardioselectivity of atenolol in asthmatic patients. **Ellis ME**, Sahay JN, Chatterjee S, Cruikshank JM, and Ellis SH. *Eur J Clin Pharm* 1981; 21: 173-176

Oxprenolol-hydrallazine interactions. Dart AM, Chiang CS, **Ellis ME**, Hawksworth GM, et al. *Br J Pharm* 1982; 13: 587P-588P

Chronic or fatal Q-fever infection: A REVIEW OF 16 PATIENTS SEEN IN North-East Scotland(1967-1980) **Ellis ME** and Smith CC. *Q J Med* 1983; 4: 54-66

The ESR in the diagnosis and management of the polymyalgia rheumatica/giant cell arteritis syndrome. **Ellis ME**, Ralston S. *Ann Rheum Dis* 1983; 42: 168-170

Hyperbaric oxygen treatment - 10 years experience of a Regional Infectious Diseases Unit. **Ellis ME**, Mandal BK. *J Infection* 1983; 6: 17-28

Cause of death in patients admitted to hospital for pulmonary tuberculosis. **Ellis ME**, Webb AK. *Lancet* 1983; 64: 665-667

The effect of cimetidine on the relative cardioselectivity of atenolol and metoprolol in asthmatic patients. **Ellis ME**, Hussain M, Webb AK, Barker NP, Fitzsimons TJ. *Br J Clin Pharmacol* 1984; 17 (suppl 1): 59s-64s

Contemporary gastroenteritis of infancy: clinical features and pre-hospital management. **Ellis ME**, Watson B, Mandal BK, et al. *Br Med J* 1984; 521-3.

*Clostridium difficile* and its cytotoxin in infants admitted to hospital with infectious gastroenteritis. **Ellis ME**, Mandal BK, Dunbar EM, et al. *Br Med J* 1984; 288: 524-526

Micro-organisms in gastroenteritis. **Ellis ME**, Watson B, Mandal BK, et al. *Arch Dis Child* 1984; 59: 848-855

Double-blind placebo-controlled trial of erythromycin in the treatment of clinical *Campylobacter* infection. Mandal BK, **Ellis ME**, Dunbar EM, et al. *J Antimicrob Chemotherapy* 1984; 13: 619-623

How well do asthma clinic patients understand their illness? **Ellis ME**, Friend JAR. *Br J Chest* 1985; 79: 43-48

An analysis of 12 months admissions to a Regional Infection Unit with an open door policy. **Ellis ME**, Burnett J, McGrath K, Smith CC. *J Infection* 1985; 10: 4-16

Adrenal function in tuberculosis. **Ellis ME**, Tayoub F. *Br J Dis Chest*, 1986; 80: 7-12 Evaluation of adenosine deaminase activity and antibody to *Mycobacterium tuberculosis* antigen 5 in cerebrospinal fluid and the radioactive bromide partition test for the early diagnosis of tuberculosis meningitis.

Coovadia YM, Dawood A, **Ellis ME**, et al. *Arch Dis Child* 1986; 61: 428-435

A comparison of the clinico-pathological features with stool pathogens in patients hospitalized with the symptom of diarrhoea.

Watson B, **Ellis ME**, Mandal BK, et al. Scand J Infect Dis 1986; 18: 553-559,

Treatment of cytomegalovirus pneumonitis with Foscarnet in patients with AIDS.

Farthing C, Anderson MG, **Ellis ME**, Gazzard BG, Chanas A. J Med Virol 1987; 22; 157-162

Neutropenia Associated with dual anti-malarial prophylaxis - Use of Bone Marrow Culture as an aid in further drug management.

**Ellis ME**, Steed A, Allison M. Journal of Infection 1987; 15: 147-52

Does isolation of patients with infections induce mental illness? Wilkins E, and **Ellis ME**. J

Infection 1988; 17: 43-7

*Mycobacteria* other than *Mycobacterium tuberculosis*.

**Ellis ME**. Current Opinion in Infectious Diseases 1988; 1: 252-271

A double-masked, placebo-controlled trial of acyclovir cream in immunocompetent patients with herpes zoster.

Mandal EK, Dunbar EM, **Ellis ME**. J Infection 1988; 17: 57-83

Infective respiratory exacerbation in young adults with cystic fibrosis: Role of viruses and atypical micro-organisms. Ong EO, **Ellis ME**, et al. Thorax 1989; 44: 739-42

An open study of interferon in HIV antibody positive men.

**Ellis ME**, et al. AIDS 1989; 3: 851-853

A review of typhoid fever in South African black children.

**Ellis ME**, et al. Post Med J, 1990;66:1032-36

Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial.

Leen CLS, Dunbar EM, **Ellis ME**, et al. J Infection, 1990;21:55-60

Echinococcal disease and mycobacterial infection.

**Ellis ME**, et al. Annals Trop Med and Parasitol, 1991;85(2):243-51

Renal transplantation associated with HIV infection: A Saudi Arabian experience and review of the literature. Barri Y, **Ellis ME**, et al. Clin Transplantation, 1991;52:33-40

Fluconazole resistant *Candida* in AIDS. Mandall BK, **Ellis ME**, et al. J Infection, 1991;22:201-04

Antibacterial activity of FCE 22101 against relatively resistant blood culture isolates.

Qadri SM, Ueno Y, **Ellis ME**. Chemotherapy, 1991;37:15-22

HIV antibody screening in a Saudi Arabian blood donor population: 5 years experience.

Bernvil SS, Sheth K, **Ellis ME**, et al. Vox Sang 1991;61:71-3

In-vitro susceptibility of clinical isolates from a tertiary care referral center to ceftizoxin and other antimicrobial agents. Qadri SH, **Ellis ME**, et al. Curr Ther Res 1991;49:644-50

In-vitro activity of lomefloxacin, a difluorinated quinolone, compared with other antimicrobials. Qadri SH, Lee GC, **Ellis ME**. Chemotherapy 1991;37:166-74

HTLV1 Antibody testing in a Saudi Arabian blood donor population. Bernvil S, **Ellis ME**, Kariem A et al. Ann Saudi Med 1991;11:647-65

Double-blind randomised study of the effect of infusion rates on toxicity of Amphotericin B. **Ellis ME**, et al. Antimicrob Chemother 1992;36:172-79

A clinical-radiological evaluation of benzimidazoles in the management of *Echinococcus granulosus* cysts. **Ellis ME**, Sinner W, Hokail A, et al. Scand J Infect Dis 1992;24:1-13.

Legionnaires Disease in Riyadh, Saudi Arabia. Halim MA, **Ellis ME**, Bouchama A et al. Saudi Med J 1993; 14(3):216-219.

Chronic hepatitis NANB complicated end-stage renal failure treated with recombinant interferon alpha. **Ellis ME**, Alfurayh O, Halim MA et al. J Hepatol 1993;18:210-16.

Histologically advanced chronic non A non B hepatitis treated with recombinant alpha interferon. A randomized placebo controlled double blind cross-over study. Sieck J, **Ellis ME**, Alfurayh O, Halim MA et al. J Hepatol 1993;19:418-23.

Tuberculosis of peripheral joints : a dilemma in diagnosis. **Ellis ME**, El-Ramahi KM, Al-Dalaan AN. Tubercle and Lung Disease 1993; 74:399-404.

Beta-lactamase production in recent clinical isolates of *Haemophilus influenzae* and their susceptibility to Cefaclor and other antimicrobial agents. Qadri SMH, Lee GC, **Ellis ME**. Saudi Med J 1993;14(1):59-61.

HIV infection in Saudi Arabia : Occurrence, pattern of disease and future implications. **Ellis ME**, Halim MA, Frayha H et al. Saudi Med J 1993;14(4):325-333.

*Mycobacteria* other than tuberculosis producing disease in a tertiary referral hospital in Saudi Arabia. **Ellis ME** and Qadri SMH. Annals Saudi Med 1993;13(6):508-515.

Controlled study of fluconazole in the prevention of fungal infections among neutropenic patients with haematological malignancies and bone marrow transplant recipients. **Ellis ME**, et al. Eur J Clin Microbiol and Infect Dis 1994;13(1):3-11.

The effect of fluconazole as prophylaxis for neutropenic patients on the isolation of *Candida* spp from surveillance cultures. **Ellis ME**, Qadri SMH, Spence D, Halim MA, Ernst PE, Clink H, Baillie F, De Vol EB. J Antimicrob Chemotherapy 1994;33:1223-8.

Hyperbaric oxygen treatment in Saudi Arabia. **Ellis ME** et al. Saudi Med J 1995;16:319-25.

Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever. **Ellis ME** et al. J Infection 1995;30:141-6.

Impact of hepatitis C virus infection on kidney transplant outcome. Alfuraygh, O, Sobh M, Chaudry T, Qunibi W, Al-Meshari K, **Ellis M** et al. Saudi J Kidney Dis Transpl, 1995; 6: 183-189.

Open lung biopsy provides a higher and more specific diagnostic yield compared to broncho-alveolar lavage in immunocompromised patients.

**Ellis ME**, Spence D, Bouchama A et al. Scand J Infect Dis 1995;27:157-62.

High incidence of line-related infection and mechanical failure of an antiseptic impregnated central venous catheter in highly immunocompromised patients. **Ellis ME**, Rhydderch D and Zwaan F. Sc J Infect Dis, 1996;28:91-93.

Bone marrow morphologic findings in patients with human immunodeficiency virus (HIV) infection. Khalil S, Nounou R, Halim M, **Ellis ME** et al. Ann Saudi Med, 1996;16:16-19

High proportion of multi-drug resistant *Mycobacterium tuberculosis* in Saudi Arabia.

**Ellis ME**, Hajar S, Bokhari H, Qadri SMH. Scand J Infect Dis 1996; 28: 591-595

Variability of serum fluconazole levels in patients with haematological malignancy or undergoing bone marrow transplantation. **Ellis ME**. et al. Clin Infect Dis 1997; 24:86-87

Pharmacokinetics of oral Fluconazole when used for prophylaxis in bone marrow transplant recipients. El-Yazigi A, **Ellis ME**, Ernst P et al. Antimicrobial Agents Chemotherapy 1997; 41: 914-917

Effect of repeated dosing on the pharmacokinetics of oral fluconazole in Bone Marrow Transplant patients. El-Yazigi A, **Ellis ME**, Ernst P et al. J Clin Pharmacol 1997; 37: 1031-1037

An EORTC International Multicenter Randomised Trial [EORTC number 19923] comparing twodosages of Liposomal amphotericin B for treatment of Invasive Aspergillosis **Ellis ME**, Spence D, de Pauw B et al. Clin Infect Dis 1998;27: 1406 – 1412.

An EORTC multicentre prospective survey of Invasive Aspergillosis in haematological patients: diagnosis and therapeutic outcome. Denning DW, Marinus A, Cohen, **Ellis ME** et al. J Infection 1998;37: 173 – 180

Antibody responses in adult patients with chronic liver disease vaccinated with hepatitisB, pneumococcal, *Haemophilus B* and meningococcal vaccines – a pilot prospective study. **Ellis ME**, Rezeig M, Zwaan F et al. EMJ 2001; 19: 43 – 49.

Fungal endocarditis: evidence in the world literature 1965 – 1995. **Ellis ME**, Abdely H, Sandridge A et al. Clin Infect Dis 2001; 32: 50 – 62.

Invasive fungal infections: evolving challenges for diagnosis and therapeutics. **Ellis ME**. Molecular Immunology 2001; 38: 947-957.

The role of early chest radiography and Chest CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis.

Hauggaard A, **Ellis ME**, Ekelund L. Acta Radiologica 2002; 43:292-298.

Recombinant human interleukin 11 and bacterial infection in patients withHaematological malignant disease undergoing chemotherapy.

**Ellis M**, Zwaan F, Hedstrom U et al. Lancet 2003, 361: 275-280.

Epidemiology, presentation, management and outcome of candidemia in a tertiaryCare teaching hospital in the United Arab Emirates, 1995-2001.

**Ellis M**, Hedstrom U, Jumaa P, Bener A. Medical Mycology 2003;41:521-528



An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. Oude Lashof AML, De Bock R, Hebrecht R, **Ellis M**, et al. European Journal of Cancer 2004;40:1314-1319

Selective induction of pentraxin 3, a soluble innate immune pattern recognition receptor, in infectious episodes in patients with haematological malignancy. Al-Ramadi BK, **Ellis M**, Pasqualini F, Mantovani A. Clinical Immunology 2004;112:221-224

Significance of the CC chemokine rantes in patients with hematological malignancy: results from a prospective observational study. **Ellis M**, al-Ramadi B, Hedstrom U, et al. BrJ Haematol 2005; 128: 482-489

Invasive fungal infections are associated with severe depletion of circulating RANTES. **Ellis M**, al-Ramadi B, Hedstrom U, et al. J Med Microbiol 2005; 54: 1017-1022

Demographics and Microbiological profile of Pneumonia in the UAE. Al-Muhairi S, Zoubeidi T, **Ellis M**, et al. Monaldi Archives for Chest Disease 2006; 65: 13-8

An open study of the comparative efficacy and safety of Caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with hematological malignancy, **Ellis M** et al. J Med Microbiol, 2006 , 55: 1357-1365

Modulation of the systemic inflammatory response by recombinant human interleukin-11:A prospective randomized placebo controlled clinical study in patients with hematological malignancy. **Ellis M**, Hedstrom U, Frampton C et al. Clin Immunol 2006 , 120 : 129-137.

EORTC Guidelines for the use of granulocyte-colony stimulating factors to reduce the Incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Aapro MS, Cameron DA, Pettengell R, Bohlius J, CrawfordJ, **Ellis M**, et al. Eur J Cancer 2006, 42: 2433-2453

Risk factors predicting outcome in patients with pneumonia in Al-Ain, United Arab Emirates. Al-Muhairia, Zoubeidi TA, **Ellis ME** et al. Saudi Med J 2006; 27: 1044-8

Assessment of the clinical utility of serial  $\beta$ -D-glucan concentrations in patients with persistent neutropenic fever. **Ellis M** et al. J Med Microbiol 2008 ; 57 : 287-295.

Febrile Neutropenia: evolving strategies.  
**Ellis ME**. Ann NY Acad Sci 2008; 1138: 329-350

Prospective evaluation of mannan and anti-mannan antibodies for diagnosis of invasive Candida infections in patients with neutropenic fever. **Ellis M** et al J Med Microbiol 2009 ;58 : 606-615.

A safety and feasibility study comparing intermittent high dose with daily standard dose liposomal amphotericin B for persistent neutropenic fever.  
**Ellis M** et al. J Med Microbiol 2009, 58 : 1474-1485.

Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults : a first critical step for rational design of innovative regimens. Hope W, Goodwin J, Felton T, **Ellis, M**, Stevens D. Antimicrob Agents Chemother 2012 ;56(10) :



## CASE STUDIES OF < 5 SUBJECTS AND CASE REPORTS

Chloramphenicol resistant *Salmonella typhimurium* meningitis in an adult.

**Ellis ME**, Smith CC, Reid TMS, Porter IA. Br Med J 1981; 2: 273-274

Transient ischaemic attacks related to egg consumption.

**Ellis ME**, Stevens DL. Postgraduate Med J 1981 57: 642-644

Progressive lung Disease in a Malt Worker. **Ellis ME** and Friend JAR. Thorax 1981; 36: 552-553

Tuberculosis meningitis following pericardiectomy for constrictive pericarditis.

**Ellis ME**, Roscoe P. Scot Med J 1981; 26: 62-64

*Streptococcus faecalis* meningitis - a salutary case.

**Ellis ME**, Glover S.C., Smith C.C., and Reid T.M.S. Scot Med J 1981; 26:262-264

Management of Gastroenteritis at Home.

**Ellis ME**, Pope J, Benjamin S. Br Med J 1981; 2: 1606

Cardioselectivity in asthmatic patients

**Ellis ME**, Sahay JN. Cruikshank JM, Ellis S. Thorax 1981, 36: 228

*Campylobacter* colitis and erythema nodosum.

**Ellis ME**, Pope J, Dunbar EM, and Mokashi A. Br Med.J. 1982; 2: 937-938

Unusual presentations of tuberculosis.

**Ellis M.** Practitioner 1982; 226: 139-143

In vivo response of acute Q fever to erythromycin.

**Ellis ME**, Dunbar EM. Thorax 1982; 37: 867-868

Hyponatraemia in Legionnaire's Disease.

**Ellis ME**, Dunbar EM, Watson B. Br Med J 1982; 1: 1047

Pseudomembranous colitis in a 5 week old infant. Mandal

BK, Watson B, **Ellis ME**. Br Med J 1982; 1: 345-346

Therapy for post-infective haemolysis.

**Ellis ME**, Smith CC. J Infection 1982; 4: 264-265

Paediatric laryngeal tuberculosis. **Ellis ME**, Dunbar EM, Hussain M. Tubercle 1983; 64: 37-39

*Clostridium difficile* colitis unassociated with antibiotic therapy. **Ellis ME**, Watson B, Milewski P. Br

J Surg 1983; 6: 17-28

Toxoplasmosis associated with digital vasculitis and immunodeficiency - a dilemma in diagnosis. **Ellis ME**, Webb AK, Dunbar EM. Postgraduate Med J 1984; 60: 46-47

Response of early disseminated herpes simplex to acycloguanosine.

**Ellis ME**, Mackanjee M. Ann Trop Paed 1985; 5: 49-50

- Transient atrial fibrillation in *Campylobacter jejuni* infection . Kell RJA, **Ellis ME**. Br Med J 1985; 291:1542
- Polymicrobial infection in enteritis. **Ellis ME**, Mandal BK, Brennan J. Br Med J 1985; 291: 1650
- Toxic epidermal necrolysis associated with streptococcal septicaemia. Wright K.U. and **Ellis ME**. Br Med J 1985; 291: 312-313
- Vivax* malaria acquired in Trinidad - a malaria-free area. **Ellis ME**, et al. Br Med J 1986; 292:1048-1049
- Use of intravenous normal immunoglobulin in high doses as possible safer alternative to oral steroids in managing LAV/HTLVIII associated immune thrombocytopenic purpura. **Ellis ME**, Flegg PJ, Alderson D. J Infection 1986 13; 312-313
- Infection of cardiac mural thrombus associated with left ventricular aneurysm. Schofield P, Rahman A, **Ellis ME**, et al. Eur Heart J (1986) 7; 1077-1082
- Is smoking a risk factor for pneumonia in adults with chickenpox? **Ellis ME**, Neal K, and Webb AK. Br Med J 294:1002, 1987
- Acyclovir and Pregnancy. Leen CLS, Mandal BK, and **Ellis ME**. Br Med J 1987;: 308
- Alpha 2 a Recombinant Interferon in HIV associated thrombocytopenia. **Ellis ME**, et al. Br Med J 1987; 295: 1519
- Porphyria cutanea tarda in association with the human immunodeficiency virus infection. Ong EO, **Ellis ME**, et al. Post Med J 1988; 64: 956-7
- Cytomegalovirus cholecystitis and colitis associated with the acquired immunodeficiency virus. Ong EO, **Ellis ME**, et al. J Infection 1989; 18: 73-75
- Neurological complication of *Mycoplasma pneumoniae* infection. Ong EO, **Ellis ME**, et al. Resp Med 1989; 83: 441-2
- Acute schistosomiasis (Katayama Fever): corticosteroid as adjunct therapy. Ong EO, **Ellis ME**. Scand J Infect Dis 1989; 21: 473-4
- Syphilitic retinitis in a homosexual man with concurrent HIV infection. Joyce PW, Haye KR, **Ellis ME**. Genitourin Med 1989; 65: 244-7
- Red Man syndrome associated with Amphotericin B. **Ellis ME**, Tharpe W. Br Med J, 1990; 330: 1468
- Fluconazole resistant *Candida* in AIDS. Fox R, Neal K, Lean L, **Ellis M** et al. J Infection 1990;22: 202-203.
- Acute natural valve endocarditis due to *Corynebacterium* group I in a normal competent host. **Ellis ME**. Eur Heart J, 1991;12:842-43
- Diagnostic dilemma and therapeutic non-compliance in a case of intracranial tuberculoma. **Ellis ME**, Halim MA, Coates RK et al. Tubercle 1991;72:299-303

Localised pulmonary disease to *Trichosporon beigelii*.  
Qadri S, **Ellis ME**. J Nat Med Assoc 1992;84:449-452

Miliary *Pneumocystis carinii* pneumoniae in AIDS. Ong  
EO, Murray H, **Ellis ME**. Int J STD + AIDS 1992;54-55

Progressive chronic necrotizing aspergillosis.: a diagnostic and therapeutic challenge. **Ellis ME**, Dossing M, Al-Hokail, A, Qadri SH, Hainau B, Burnie J. J Roy Soc Med 1992;85:763-764.

Cellulitis caused by *Enterobacter cloacae*.  
Ganelin R and **Ellis ME**. J Infection 1992;24:218-219

Clinical significance of atypical *Mycobacteria* in human disease. Qadri  
SMH and **Ellis ME**. Infect Dis Practice 1992;16(10)1-11.

Liposomal amphotericin B treatment of aspergillosis in a renal transplantation patient. **Ellis ME**,  
Bohlega S et al. Saudi Med J 1993; 14(5):469-470.

Hodgkin's lymphoma complicating HIV infection.  
Khuwatir T, **Ellis ME**, Clink H et al. Saudi Med J 1993;14(5):466-468.

Retrovir prophylaxis for HIV exposure to Health Care Staff.  
**Ellis ME**, Halim MA, Rabiah F et al. Saudi Med J 1993; 14(4):384-385.

Acute renal failure with alpha-interferon therapy - a case report. Ayub  
A, Zafar M, Al-Harbi A, **Ellis ME** et al. Med Sci Res 1993

*Brucella* peritonitis.  
Halim M, Ayub A, Abdulkareem A, **Ellis ME** et al. J Infection 1993;27:169-172.

Is Cyclosporin neurotoxicity enhanced in the presence of liposomal amphotericin B?  
**Ellis ME** et al. J Infection 1994;29(1):106-107.

Successful combined surgical and medical treatment of *Fusarium* infection after bone marrow  
transplantation. **Ellis ME** et al. Scand J Infect Dis 1994;26:225-228.

Hypercalcaemia associated with cytomegalovirus infection in an AIDS Patient.  
Fallatah, S, Halim, MA, **Ellis, ME**. J Acquired Immune Def Syn Hum Retrovir 1995; 8: 101 - 102

*Stomatococcus mucilaginous* meningitis in a patient with acute lymphoblastic leukemia. Fiar F,  
**Ellis ME** et al. Ann Saudi Med 1995; 15: 393-395

*Enterobius vermicularis* and acute appendicitis.  
Al-Rabiah F, Halim M, **Ellis ME** et al. Saudi Med J 1996;17: 795 - 799

Severe plantar fasciitis successfully treated with hyperbaric oxygen.  
**Ellis ME** et al. Saudi Med J 1996; 17: 810

High level, multi resistant enterococci associated with systemic disease - a report of two cases.  
Quadri SMH, **Ellis ME**. Ann Saudi Med 1996; 16: 682-684.

Craniocervical junction tuberculosis – a rare but dangerous disease.

Kanaan I, **Ellis ME**, Safi T et al. Surg Neurol 1999;51: 21 – 26

Hyperbaric oxygen can be effective in treating post partum necrotising fasciitis Type 1.

**Ellis ME**. J Infection 2000; 40: 292 -293

Massive intracerebral aspergillosis responding to combination high dose liposomal amphotericin B and cytokine therapy without surgery.

**Ellis ME**, Watson K, McNabb A et al. J Med Microbiol 2001; 51: 70-75

Severe hepatic injury associated with lipid formulations of amphotericin B.

**Ellis ME**, Shammon A, Gorka W et al. Clin Infect Dis 2001; 32: E87 – E89

Invasive infection due to Penicillium species other than P. marneffei.

Lyratzopolous G, **Ellis M**, Neringer R. J Infection 2002; 45:184-207

Role of staphylococcal enterotoxin A in a fatal case of endocarditis.

**Ellis M**, Serreli A, Colque-Navarro et al. J Med Microbiol 2003; 52: 1-4

Impact of hepatitis C virus infection on kidney transplant outcome. Alfurayh OI, SobhMAE,

Chaudry TS, Qunibi WY, Al-Meshari K, **Ellis M**, et al. Saudi Med J 2003;24:S128

Pulmonary Nocardiosis masquerading as severe community-acquired pneumonia.

Kamel S., Al-Kaabi J., **Ellis M.**, Gariballa, S. Eur J Emerg Med 2010; 17: 302-303.

## REVIEWS

Infantile gastroenteritis: A review with emphasis on management.

**Ellis ME.** Physician India, 1986; 3: 196-202

Whats new in enteric infections? **Ellis ME.** Hospital Update, 1989 Feb 129-141 Rubella.

**Ellis ME.** The Practitioner, 1990;234:906-10

Fungal Endocarditis.

**Ellis M.** J Infection 1997; 35: 99-103

Therapy of *Aspergillus fumigatus* related diseases. **Ellis M.** Contrib Microbiol 1999 (2): 105-129.

Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections?

**Ellis ME.** Transplant Infection 2000; 2: 51 – 56

Epidemiology of invasive fungal infections.

**Ellis ME,** Richardson M, de Pauw B. Hospital Medicine 2000; 61: 605 – 609

Management of invasive fungal infections.

**Ellis ME,** Richardson MK. Hospital Medicine 2000; 61: 615 – 619

Fungi, mycological disease and pathogenic determinants.

Richardson M, **Ellis ME.** Hospital Medicine 2000; 600 – 604

Clinical and laboratory diagnosis of invasive fungal infections.

Richardson M, **Ellis ME.** Hospital Medicine 2000; 610 – 614

Preventing microbial translocation in haematological malignancy. **Ellis ME.** Br J Haematol 2004;125:282-293.

Fungal infections.

**Ellis M.** In Encyclopedia of Gastroenterology. Academic Press.2004;79-82.

New dosing strategies for liposomal amphotericin B in high-risk patients.

**Ellis M.** Clin Microbiol Infect 2008; 14(S): 55-64.

## EDITORIALS

Hyperbaric oxygen therapy - the Cinderella in the management of anaerobic infections.  
**Ellis ME**, and Mandal BK. J Infection 1983; 6: 1-3

AIDS and the foreign traveller. **Ellis ME**. Travel Medicine International 1987; 5: 57-60

Malaria. **Ellis ME**. Arch Emerg Med 1988; 5: 195-9

Non A Non B hepatitis - quandaries in serological testing and treatment.  
**Ellis ME**. J Infection, 1990;21:235-40

Non A Non B hepatitis and hepatitis C: relationship, serodiagnosis, pitfalls and challenge of treatment  
**Ellis ME**. Saudi Med J 1991;11:489-93

Amphotericin B and invasive aspergillosis: how does the data guide us?  
**Ellis ME**. J Med Microbiol 2002; 51: 95-97



## LETTERS TO THE EDITOR AND OTHER PUBLICATIONS

Infectious Disease Management in Britain. **Ellis ME**. Lancet 1982; 2: 1403

Recognise inherent toxicity problems of antiviral agents. **Ellis ME**. 1983; 15 May: 66-73

Contribution to UK national television and radio programmes on AIDS 1984.

Vaccinating against viruses. **Ellis ME**. MIMS Magazine, 1985 (15 August): 19-22

AIDS and you - for Health Care Personnel:

Video; North Manchester Department of Medical Illustration, 1985.

Personal View. **Ellis ME**. Br Med J 1986, 293-1303

AIDS - The Reality and the Myth: Master Class Video Cassettes, 1986.

Infectious and Tropical Diseases MCQs in MRCP part 1: multiple choice questions with individual subject summaries. Edited by O'Neill P. PASTEST. 1987. ISBN 0 0906896 55X

Rio de Janeiro - Progress in infectious Disease Report.

**Ellis ME**. Hospital Update 1988, 1873-1874

Whither the specialist in infection. **Ellis ME**. J Infection 1989; 18: 293-301

Interferon treatment for chronic viral hepatitis. **Ellis ME**. Hospital Update, 1990

AIDS - A Guide for Physicians: King Faisal Specialist Hospital and Research Centre 1990

A complication of oral surgery. Medical Case Reports from the King Faisal Specialist Hospital and Research Center. Vol 1; 1 - 2. 1992 .Ed Sieck JO and Saour J.

*Clostridium difficile* enterocolitis. Medical Case Reports from the King Faisal Specialist Hospital and Research Center. Vol 1; 2 - 4. 1992 .Ed Sieck JO and Saour J.

Department of Medicine Manual. Tawam Hospital, UAE 1999 (available as an e-version).

Liposomal amphotericin B: The argument for using the minimal effective dose.

**Ellis ME**. Round table series 1999; #65: 37 - 44 Roy Soc Med.

Ib'n Sina Rounds [Pneumothorax]. **Ellis ME**. EMJ 2000; 18: 246-247.

Ib'n Sina Rounds [Toxoplasmosis]. **Ellis ME**. EMJ 2001; 19: 213-214.

Clinical Research in the Lay Press: Irresponsible Journalism raises a huge dose of doubt. Anaissie EJ, **Ellis ME** et al. CID 2006 ; 43 : 1031-9

Febrile neutropenia: current challenges. **Ellis M**. Em Med J 2007 (1 Suppl): 25.

Use of Antibiotics: King Faisal Specialist Hospital and Research Centre, 1991.

*Aspergillus* Endocarditis. The *Aspergillus* website. <http://www.aspergillus.man.ac.uk> 2001

Guidance on Antibiotic Use in Adults.

Eley, A., Ellis, M. et al. FMHS, Al Ain Hospital, Tawam Hospital. 2007.

## TEXTBOOKS AND CHAPTERS IN TEXTBOOKS

Infectious Diseases of the Respiratory Tract: Cambridge University Press Editor **Ellis ME** 1998.  
ISBN 0 521 40554 8

### CHAPTERS IN INFECTIOUS DISEASES OF THE RESPIRATORY TRACT:

Staphylococcal pneumonia. **Ellis ME**

Viral Lower Respiratory Tract Infections. **Ellis ME**Gram

Negative Bacillary Pneumonia. **Ellis ME**

Cytomegalovirus Pneumonia. **Ellis ME**

Non-tuberculous *Mycobacteria*. **Ellis ME**, Frotheringham R Actinomycosis  
and Nocardiosis. **Ellis ME**

Fungal Respiratory Disease. **Ellis ME**

Hospital Acquired Pneumonia. Miller G, **Ellis ME**

Anaerobic Lung Infection, Lung Abscess and Empyema. Khan J, **Ellis ME**

Pneumonia in the Immunocompromised. **Ellis ME**

Upper Respiratory Tract Infections. **Ellis ME**, McArthur P

Diseases Associated with Persistent or Recurrent Pulmonary Infiltrates. **Ellis ME**

Miscellaneous Pneumonic Agents and Others Causing Lower Respiratory Tract Infection.  
**Ellis ME**

Fever in a patient with prosthetic valve replacement.  
**Ellis ME**. Chapter, Textbook of Medicine with King Faisal University, Dammam, 1994

A diarrhoeal illness.  
**Ellis ME** Chapter, Textbook of Medicine with King Faisal University, Dammam, 1994

**Ellis, M.** Leptospirosis. In 'Clinical Medicine'. Online Chapter. Editors Kumar P and Clark M.  
6<sup>th</sup> edition  
Elsevier Saunders 2005.

**Ellis, M.** Human Avian Influenza Infection. In 'Clinical Medicine'. Online Chapter. Editors  
Kumar and Clark M. 7<sup>th</sup> edition. Elsevier Saunders 2009.

**Ellis, M.** Thomas Cranmer and his Eucharistic Theology: A Review and Discussion. Dissertation  
submitted in partial fulfilment for the degree of BA (Honours) Theology, University of Gloucestershire 2011.

# REFEREES (OTHERS ARE ALSO AVAILABLE ON REQUEST)

1. Professor Gary Nicholls  
FRACP Department of Medicine  
University of Otago/Christchurch  
Christchurch Hospital  
Riccarton Avenue  
Christchurch  
New Zealand  
[Gary.Nicholls@cdhb.govt.nz](mailto:Gary.Nicholls@cdhb.govt.nz)  
0064 3366 8694
  
2. Professor Basel al-Ramadi FRCPath  
Professor and Chairman  
Department of Medical Microbiology and Immunology  
Faculty of Medicine and Health Sciences  
United Arab Emirates University  
POBox 17666  
Al Ain  
United Arab Emirates  
[ramadi.b@uaeu.ac.ae](mailto:ramadi.b@uaeu.ac.ae)  
009713 713 7529
  
3. Professor David Lloyd  
FRCPConsultant  
Gastroenterologist Manitoba  
Clinic  
790 Sherbrook Street  
Winnipeg MB  
R3A 1MB  
Canada  
[dlloyd@mymts.net](mailto:dlloyd@mymts.net)  
001 204 788 5713
  
4. David Brown  
Assistant Director of Operations  
Chief Executive Office  
Derriford Hospital NHS Trust  
Plymouth  
PL6  
8DH  
UK  
[david.brown29@nhs.net](mailto:david.brown29@nhs.net)  
0044 1752 439462

5. Dr Austin Hunt  
Consultant in Acute medicine and Clinical Lead  
Acute Medical Unit  
Derriford Hospital NHS  
TrustPlymouth  
PL6  
8DH  
UK  
[austin.hunt@nhs.net](mailto:austin.hunt@nhs.net)  
0044 1752 49290

## REFEREE FOR MEDICOLEGAL ACTIVITIES

Dr Michael Powers KC  
The Lodge  
Lopwell Dam  
Maristow  
Plymouth  
PL6 7BZ  
[powersqc@medneg.co.uk](mailto:powersqc@medneg.co.uk)  
Tel 0044 1752 733 018